灰指甲治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年全球甲癣治疗市场规模达42亿美元，预计2034年将以5.3%的复合年增长率成长至69亿美元。推动这一市场成长的因素包括：全球范围内甲癣盛行率的不断上升、人们对甲真菌感染风险认识的不断提高，以及药物疗法的日益普及。与年龄相关的甲癣病例的增加进一步支持了这一市场的扩张。此外，线上药局使用量的激增和消费者对自我治疗的偏好也推动了市场的发展，因为透过电商平台取得非处方 (OTC) 抗真菌药物变得更加容易。此外，糖尿病发生率的上升也促进了市场的成长，由于免疫系统功能减弱和血液循环不良，糖尿病会增加甲癣的风险。

人口老化正日益成为指甲真菌感染发生率上升的关键因素。随着年龄的增长，人们的免疫系统往往会减弱，使他们更容易受到感染，包括甲癣。与年龄相关的因素，例如血液循环减少、指甲生长减缓以及皮肤屏障功能下降，都会增加真菌感染的风险。此外，老年人更容易患糖尿病或血液循环不良等疾病，这两者都会进一步增加指甲真菌感染的可能性。随着老龄化人口需要更多地关注其医疗保健需求，包括预防和管理这些感染，对有效治疗的需求也在增长。

2024年，药品市场价值达32亿美元。口服抗真菌药物被视为甲癣的一线治疗药物，其受欢迎程度正推动该市场的成长。伊曲康唑、特比萘芬、灰黄霉素和酮康唑等药物应用广泛，且在药局易于获取，促进了市场需求。人们对与甲癣相关的指甲健康和美容问题的日益重视也推动了对有效药物的需求。

远端甲下型甲癣 (DSO) 占据了 2024 年最大的市场份额，达 68.3%。 DSO 是最常见的甲癣类型，会影响糖尿病患者和周边循环功能减退等疾病患者，使他们更容易感染。随着全球人口老化，预计 DSO 病例将会增加，这将进一步推动对局部和全身性抗真菌治疗的需求。

2024年，美国甲癣治疗市场规模达16亿美元。该地区的高成长得益于人们对甲真菌感染认识的提高以及各种治疗方案的普及。出于对美观和卫生的追求，人们寻求早期发现和及时治疗，以降低传播率和相关併发症。美国广泛的治疗方案预计将在整个预测期内继续支持该地区的市场扩张。

甲癣治疗市场的一些主要参与者包括 Taro Pharmaceuticals、葛兰素史克、强生服务、Azilda Family Foot Care、Merz Pharma、博士伦健康科学、诺华、高德美实验室、雷迪博士实验室、Moberg Pharma、Kaken Pharmaceuticals、Skin Logic Aesthetics、南夏洛特综合血管外科和辉瑞。综合血管外科和辉瑞。综合血管外科和辉瑞。综合血管外科和辉瑞。综合血管外科和辉瑞。综合血管外科和辉瑞。综合血管外科和辉瑞。在甲癣治疗市场，公司正在采取多种策略来巩固其地位。这些措施包括扩大产品供应、专注于研发以推出新疗法以及透过线上药局增加其影响力。与电子商务平台和零售连锁店合作以加强分销也是关键策略，同时投资于消费者意识活动，教育患者了解甲癣的风险和治疗方法。此外，公司正在优化生产流程，以确保提供负担得起的高品质治疗，这对于在竞争激烈的环境中抢占市场份额至关重要。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 甲癣盛行率不断上升
    • 治疗方案的进步
    • 人们对甲癣潜在威胁的认识不断提高
    • 越来越注重美观
  • 产业陷阱与挑战
    • 发展中地区缺乏意识
    • 甲癣治疗药物的副作用
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供给侧影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按治疗类型，2021 - 2034 年

• 主要趋势
• 药物
  • 口服抗霉菌药物
  • 外用抗真菌药物
• 雷射和光动力疗法
• 手术

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

• 主要趋势
• 远端甲下甲癣
• 近端甲下甲真菌病
• 白色表浅性甲真菌病
• 其他疾病类型

第七章：市场估计与预测：依性别，2021 - 2034 年

• 主要趋势
• 男性
• 女性

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 皮肤科诊所
• 居家照护环境
• 门诊手术中心

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Azilda Family Foot Care
• Bausch Health Sciences
• Dr. Reddy's Laboratories
• Galderma Laboratories
• GlaxoSmithKline
• Johnson & Johnson Services
• Kaken Pharmaceuticals
• Merz Pharma
• Moberg Pharma
• Novartis
• Pfizer
• Skin Logic Aesthetics
• South Charlotte General and Vascular Surgery
• Taro Pharmaceuticals

The Global Onychomycosis Treatment Market was valued at USD 4.2 billion in 2024 and is estimated to grow at a CAGR of 5.3% to reach USD 6.9 billion by 2034.This market growth is driven by the increasing prevalence of onychomycosis worldwide, heightened awareness about the risks associated with nail fungal infections, and the growing adoption of drug therapies for treatment. The rise in age-related cases of onychomycosis further supports this market expansion. Additionally, the surge in online pharmacy usage and consumer preference for self-treatment has propelled the market, as it has become easier to access over the counter (OTC) antifungal medications via e-commerce platforms. Furthermore, the rising incidence of diabetes, which heightens the risk of onychomycosis due to weakened immune systems and poor circulation, is also contributing to the market's growth.

The aging population is increasingly becoming a key factor in the rising incidence of nail fungal infections. As individuals age, their immune systems often weaken, making them more susceptible to infections, including onychomycosis. Age-related factors such as reduced blood circulation, slower nail growth, and a decline in skin barrier function contribute to the higher risk of developing fungal infections. Moreover, older adults are more likely to suffer from conditions like diabetes or poor circulation, both of which further elevate the likelihood of fungal nail infections. The demand for effective treatments is growing as the aging population requires more attention to their healthcare needs, including the prevention and management of these infections.

The drug segment was valued at USD 3.2 billion in 2024. The popularity of oral antifungal agents, which are considered the first-line treatment for onychomycosis, is fueling this segment's growth. Medications like itraconazole, terbinafine, griseofulvin, and ketoconazole are widely used, with easy availability in pharmacies enhancing market demand. The growing emphasis on nail health and cosmetic concerns related to onychomycosis also boosts the need for effective drugs.

The distal subungual onychomycosis (DSO) segment accounted for the largest market share of 68.3% in 2024. As the most common form of onychomycosis, DSO affects individuals with conditions such as diabetes and those with reduced peripheral circulation, which makes them more prone to infections. As the global population ages, DSO cases are expected to increase, further driving the need for both topical and systemic antifungal treatments.

U.S. Onychomycosis Treatment Market was valued at USD 1.6 billion in 2024. High regional growth is attributed to increased awareness of nail fungal infections and the availability of various treatment options. The demand for aesthetic appeal and hygiene drives people to seek early detection and timely treatment, reducing transmission rates and associated complications. The wide range of treatment options available in the U.S. is expected to continue supporting market expansion in the region throughout the forecast period.

Some of the key players in the Onychomycosis Treatment Market include Taro Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson Services, Azilda Family Foot Care, Merz Pharma, Bausch Health Sciences, Novartis, Galderma Laboratories, Dr. Reddy's Laboratories, Moberg Pharma, Kaken Pharmaceuticals, Skin Logic Aesthetics, South Charlotte General and Vascular Surgery, and Pfizer. In the Onychomycosis Treatment Market, companies are adopting several strategies to strengthen their position. These include expanding product offerings, focusing on research and development to introduce novel treatments, and increasing their presence through online pharmacies. Partnerships with e-commerce platforms and retail chains to enhance distribution are also key strategies, along with investments in consumer awareness campaigns to educate patients on the risks and treatments for onychomycosis. Moreover, companies are optimizing manufacturing processes to ensure the availability of affordable and high-quality treatments, which is crucial for capturing market share in the competitive landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of onychomycosis
    • 3.2.1.2 Advancement in treatment options
    • 3.2.1.3 Growing awareness about the potential threats of onychomycosis
    • 3.2.1.4 Increasing focus on aesthetic appearance
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of awareness in developing regions
    • 3.2.2.2 Side effects associated with onychomycosis treatment drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Oral antifungal drugs
  • 5.2.2 Topical antifungal drugs
• 5.3 Laser and photodynamic therapy
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Distal subungual onychomycosis
• 6.3 Proximal subungual onychomycosis
• 6.4 White superficial onychomycosis
• 6.5 Other disease types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Dermatology clinics
• 8.4 Homecare settings
• 8.5 Ambulatory surgical centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Azilda Family Foot Care
• 10.2 Bausch Health Sciences
• 10.3 Dr. Reddy's Laboratories
• 10.4 Galderma Laboratories
• 10.5 GlaxoSmithKline
• 10.6 Johnson & Johnson Services
• 10.7 Kaken Pharmaceuticals
• 10.8 Merz Pharma
• 10.9 Moberg Pharma
• 10.10 Novartis
• 10.11 Pfizer
• 10.12 Skin Logic Aesthetics
• 10.13 South Charlotte General and Vascular Surgery
• 10.14 Taro Pharmaceuticals